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Summary — The 2001 European Commission proposal for the Registration, Evaluation and Authorisation
of Chemicals (REACH) aims to improve public and environmental health by assessing the toxicity of, and
restricting exposure to, potentially toxic chemicals. The greatest benefits are expected to accrue from
decreased cancer incidences. Hence the accurate identification of chemical carcinogens must be a top priority for the REACH system. Due to a paucity of human clinical data, the identification of potential human
carcinogens has conventionally relied on animal tests. However, our survey of the US Environmental
Protection Agency’s (EPA’s) toxic chemicals database revealed that, for a majority of the chemicals of greatest public health concern (93/160, i.e. 58.1%), the EPA found animal carcinogenicity data to be inadequate
to support classifications of probable human carcinogen or non-carcinogen. A wide variety of species were
used, with rodents predominating; a wide variety of routes of administration were used; and a particularly
wide variety of organ systems were affected. These factors raise serious biological obstacles that render
accurate extrapolation to humans profoundly difficult. Furthermore, significantly different International
Agency for Research on Cancer assessments of identical chemicals, indicate that the true human predictivity of animal carcinogenicity data is even poorer than is indicated by the EPA figures alone. Consequently,
we propose the replacement of animal carcinogenicity bioassays with a tiered combination of non-animal
assays, which can be expected to yield a weight-of-evidence characterisation of carcinogenic risk with superior human predictivity. Additional advantages include substantial savings of financial, human and animal
resources, and potentially greater insights into mechanisms of carcinogenicity.
Key words: alternative, animal experiment, animal test, bioassay, cancer prevention, carcinogenicity,
chemical classification, chemical safety, computer simulation, REACH, risk assessment.
Address for correspondence: A. Knight, Animal Consultants International, 91 Vanbrugh Court, Wincott
Street, London SE11 4NR, UK.
E-mail: info@animalconsultants.org

Introduction
The 2001 European Commission (EC) proposal for
the Registration, Evaluation and Authorisation of
Chemicals (REACH) produced or imported in quantities in excess of one tonne has two main objectives: to improve the competitiveness of the
European Union (EU) chemical industry internationally; and to provide enhanced protection for
human health and the environment from the toxic
effects of chemicals.
Some tangible estimates of the potential benefits
to human health are provided in a study conducted
for the EC’s Environment Directorate General
(DG) by Postle et al. (1). The study examined the
likely impacts of the implementation of the REACH
system on the occupational health of chemical
industry workers and downstream users of chemicals. Specifically, it estimated the likely impacts of
the REACH system on five body systems and associated diseases: the skin (eczema, allergic contact
dermatitis, irritant contact dermatitis); the respiratory system (asthma, allergic rhinitis, and other

respiratory illnesses); the eyes (conjunctivitis); the
central nervous system (CNS disorders); and 16
types of cancer death.
The precise causes of cancer are often difficult to
discern, owing to the contributions of lifestyle, environmental, occupational and genetic factors.
Nevertheless, some 32,500 cancer deaths, representing around 3.5% of the annual EU total, are
considered to arise mainly from occupational exposure to carcinogens. Around 6500 (20%) of these
32,500 deaths were estimated to arise from exposure to unknown chemical carcinogens (with the
remainder associated with known or suspected carcinogens, and thus covered by existing legislation).
Postle et al. (1) estimated that the REACH
approach might prevent between one-third and
two-thirds of these deaths within the EU annually,
i.e. between 2167 cancer deaths (0.23% of the EU
total) and 4333 cancer deaths (0.47%).
Compared with most other diseases, the human
and economic costs of cancer are very high. Based
on cost–benefit analyses carried out by DG
Environment (1), the cost of a cancer death was

A. Knight et al.

140

estimated as being between €1.39 million (lower
estimate) and €2.14 million (best estimate). These
estimates were initially sourced from the UK
Government, and were based on the amounts surveyed individuals stated they would be willing to
invest to reduce their personal risks of transportrelated fatality. Additionally, the best estimate
included some element of medical costs, and lost
production and human costs. These estimates were
then adjusted to reflect the age of those at risk of
cancer related-death (typically, elderly), and the
fact that there is usually a period of ill health prior
to a cancer death, which the individuals surveyed
also stated they would be willing to pay to avoid (a
“cancer premium”).
Not included in these estimates were the medical,
production and human costs associated with nonfatal cancer cases. Other costs which were excluded
or potentially under-estimated, included:
— diagnostic and treatment-related medical costs;
— productivity losses to employers and society;
— administrative, management and legal costs
incurred by employers; and
— government expenditure on sick pay and disability benefits.
Based on these conservative estimates of the cost of
cancer deaths, and these lower and upper estimates
of the number of cancer deaths likely to be prevented through the REACH system, the cancerrelated economic benefits of implementing the
system over 30 years were estimated by Postle et al.
(1) to be between about €18 billion and €54 billion
(Table 1).
On the other hand, the economic benefits of
implementing the REACH system for all non-cancer diseases combined were estimated to be between
€23 million and €225 million, despite the over-optimistic assumption that the number of these cases
related to unknown chemicals would be effectively
reduced to zero.
These estimates do not represent the total economic value of the REACH system, because the positive effects for wider public health and the
environment have not been incorporated. However,
it seems clear that the prevention of cancer is of
greater potential benefit to occupational health
than the prevention of all other diseases combined,

when considered from an economic viewpoint alone.
The same might also be reasonably expected of the
human costs. Consequently, the accurate identification of occupational carcinogens to which chemical
and downstream industry workers are exposed
must be a top priority for the REACH system.
Due to a paucity of human clinical data, the identification of chemical carcinogens has conventionally
relied heavily on information provided by animal
tests. However, are animal bioassays truly predictive
for human carcinogenicity? The potential savings of
thousands of lives annually within the EU, and billions of euros in human and productivity costs,
clearly demand the use of carcinogenicity assays that
offer the best possible human predictivity.
To examine the human predictivity of animal carcinogenicity data, and its utility in deriving human
carcinogenicity classifications for regulatory purposes, we surveyed the chemicals contained within
the Integrated Risk Information System (IRIS)
toxic chemicals database maintained by the US
Environmental Protection Agency (EPA). The EPA
is the federal agency most responsible for protecting Americans from environmental contaminants,
and its IRIS database contains human carcinogenicity assessments of the chemicals of greatest
US public health concern, along with the data from
which those assessments are derived.

Methods
We examined the chemicals contained within the
IRIS database that lacked significant human exposure data but possessed animal carcinogenicity data
(the great majority), and that had received a human
carcinogenicity assessment by 1 January 2004. We
determined the proportion for which the EPA was
able to derive the classifications of probable human
carcinogen or non-carcinogen, based primarily on
their animal carcinogenicity data. A 95% confidence
interval (CI) for this proportion was derived via the
modified Wald method, which is said to provide
more-accurate results than the so-called “exact”
method which is commonly used (2).
To investigate the impact of these factors on the
human utility, or otherwise, of the animal carcinogenicity data, we examined the species and routes of
administration used, and the organ systems affected.

Table 1: Estimated EU economic benefits over 30 years of reducing annual cancer deaths
through the implementation of the REACH system
Lower predicted benefit
(2167 deaths prevented annually)
Lower estimate of 30-year benefit
Best estimate of 30-year benefit
Data source: Postle et al (1).

17,592 (€ million)
27,083 (€ million)

Upper predicted benefit
(4333 deaths prevented annually)
35,183 (€ million)
54,167 (€ million)
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Results

To assess the reliability of the EPA carcinogenicity assessments, we compared them with those of
the World Health Organisation’s International
Agency for Research on Cancer (IARC). Of 128
chemicals assigned human carcinogenicity classifications by both agencies, 17 were considered by the
EPA to possess at least limited human data, while
111 were primarily reliant on animal data for their
classifications. The consistency of classifications
between the EPA and IARC was examined for each
of these two groups, by comparing the carcinogenicity classification proportions within each group via
chi-squared tests, and by comparing the individual
classifications of the 111 chemicals primarily
reliant on animal carcinogenicity data for their classifications.
Chi-squared tests provide a statistical calculation of the probability that two data sets, such as
the EPA and IARC human carcinogenicity classifications, are samples from the same underlying
data population, and that any observed differences are simply due to random sampling variation. Large chi-squared values (χ 2 ) reflect
increased probabilities that observed differences
are due to real differences in underlying data populations (3).
Chi-squared and two-tailed p values were derived
from the online statistical calculators available at
http://www.graphpad.com/quickcalcs/ index.cfm.

For 93 (58.1%; 95% CI: 50.4–65.5) of the 160 chemicals lacking even limited human data but possessing animal data, and which had received human
carcinogenicity assessments, the EPA considered
the animal data inadequate to support the substantially useful classifications of probable human carcinogen or probable human non-carcinogen (3).
The species used were available for 158 of these
chemicals. At least 10 different species were used,
namely: chicken, dog, guinea-pig, hamster, mouse,
mink, non-human primate (one macaque, three
unspecified “monkey” species, and one unspecified
“primate” species), rabbit, rat, and trout. The three
species most commonly used (Figure 1; 4) were the
mouse (92.4%), rat (86.7%), and hamster (14.6%).
The routes of administration used were available
for 156 of the chemicals. Twelve non-oral routes of
administration, and a variety of oral routes, not
always specified, were used. They were: dermal,
inhalation, intramuscular, intraperitoneal, intrapleural, intrarenal, intratesticular, intravenous,
oral: food, oral: gavage, oral: water, oral: other (for
example, capsule, toothpaste additive), oral:
unspecified, subcutaneous, surgical implantation,
transplacental, and vaginal painting. Those most
commonly used (Figure 2; 4) were food (49.4%),
gavage (33.3%), and dermal administration (26.3%).

Figure 1: Species used with assessed EPA chemicals lacking significant human data but
possessing animal data
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Data source: The EPA Integrated Risk Information System database, 1 January 2004.
Reproduced from Knight et al. (4).
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Figure 2: Routes of administration for assessed EPA chemicals lacking significant human
data but possessing animal data
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Data source: The EPA Integrated Risk Information System database, 1 January 2004.
Reproduced from Knight et al. (4).

Other routes of major interest were drinking water
(21.1%), and inhalation (17.9%).
Chemicals considered probably not carcinogenic
to humans were not, of course, known to exhibit
significantly neoplastic lesions. For those chemicals

considered unclassifiable, it was frequently difficult
to establish whether or not significant treatmentrelated results occurred. However, for the remaining 104 chemicals, considered probable or possible
human carcinogens, up to 43 organs or organ sys-
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tems were found to exhibit neoplastic lesions, with
those most commonly affected (Figure 3; 4) being
the liver (66.3%), the lung (31.7%), and the kidney,
skin and stomach (all 17.3%). It should be noted
that differentiation between primary and metastatic tumours was often impossible, so all tumours
were included, even when, infrequently, they were
identified as metastases.
128 chemicals with human or animal data were
assessed by both the EPA and the IARC. Of these
128, human carcinogenicity classifications were
similar only for those 17 with significant human
data (χ2 = 0.291, 1 df, p = 0.5896; Table 2). Note
that chi-squared analysis does not allow comparison
when one category lacks any data, hence acrylonitrile, assessed as the only possible human carcinogen by the IARC, but as a probable human
carcinogen by the EPA, was excluded, yielding a
more conservative result.
For the 111 classifications primarily reliant on
animal data, the EPA was much more likely to
assign carcinogenicity classifications indicative of
greater human risk (χ2 = 215.548, 2 df, p < 0.0001;
Figure 4; 3). To permit a chi-squared analysis,
methacrylate, assessed as unclassifiable by the
IARC, but as the only probable human non-carcinogen by the EPA, was excluded, yielding a more conservative result.
The data reveal that the EPA was much more
likely than the IARC to assign carcinogenicity classifications indicative of greater human hazard (3). The
numbers of chemicals classified by the EPA as probable human carcinogens (60 chemicals) compared to
all other categories (51 chemicals) were very significantly different from those predicted by IARC figures of 12 and 99 respectively (χ2 = 215.273, 1 df,
p < 0.0001). Similar disparities were found for possible human carcinogens (χ2 = 19.771, 1 df,
p < 0.0001) and unclassifiable chemicals (χ2 = 24.378,
1 df, p < 0.0001).
Comparison of the individual classifications of
these 111 chemicals revealed that 67 (60.4%) were
assigned an EPA carcinogenicity classification
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indicative of greater human hazard, 38 (34.2%)
were assigned an equivalent classification, and 6
(5.4%) were assigned a classification indicative of
lower human hazard, than the corresponding IARC
classifications of the same chemicals (3).

Discussion
Based on the EPA figures alone, the predictivity of
animal carcinogenicity data for human hazard, and
hence its utility in deriving substantially useful
human carcinogenicity classifications for regulatory
or other purposes, is clearly questionable. Of those
160 IRIS chemicals lacking even limited human
data but possessing animal data, the EPA considered the animal data inadequate to support the substantially useful classifications of probable human
carcinogen or non-carcinogen, in the majority (93,
58.1%) of cases. Classifications of definite human
carcinogen relied on the existence of convincing
human data. Classifications of unclassifiable or possible human carcinogen were not considered substantially useful for risk assessment or regulatory
purposes, and are excluded from the US National
Toxicology Program (NTP) annual Report on
Carcinogens (5).
A wide variety of species were used in these carcinogenicity bioassays, with rodents predominating; a wide variety of routes of administration
were used; and a particularly wide variety of organ
systems were affected. The likely causes of the
poor human predictivity of these bioassays
include: 1) the profound discordance of bioassay
results between rodent species, strains and genders, and between rodents and human beings; 2)
the substantial stresses caused by handling,
restraint and stressful routes of administration,
with consequent effects on immunocompetence
and predisposition to carcinogenesis; 3) the differences in transport mechanisms and rates of
absorption between test routes of administration
and other important routes of human exposure;

Table 2: IARC classifications of EPA chemicals possessing significant human data (EPA
categories A or B1)
Human carcinogenicity classification

EPA

IARC

Human Carcinogen (A)
Probable Human Carcinogen (B1)
Possible Human Carcinogen

11
6
0

12
4
1

Total

17

17

Data sources: The EPA Integrated Risk Information System database, 1 January 2004, and the IARC Monographs
Programme on the Evaluation of Carcinogenic Risks to Humans, Volumes 1–82, 1 January 2004.
Reproduced from Knight et al. (3).
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Figure 3: Organ systems affected by chemicals assessed by the EPA to be probable (B2) or
possible (C) human carcinogens
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over-reliant on animal carcinogenicity data; 2) as a
result, the EPA tends to over-predict carcinogenic
risk; and 3) the true predictivity for human carcinogenicity of animal data is even poorer than is
indicated by EPA figures alone (3).
EPA human carcinogenicity classifications
appear to be less scientifically-based than those of
the IARC, due to: 1) the varying depth of EPA
assessments, due to resource constraints; 2) the less
rigorous standards required of data incorporated
into EPA assessments; and 3) EPA public healthprotective policy, which errs on the side of caution
by assuming that tumours in animals are indicative
of human carcinogenicity (3).

1

probable
probable
possible
unclasshuman nonhuman
human
ifiable
carcinogen
carcinogen
carcinogen
human carcinogenicity classification

= IARC;
= EPA; * = p < 0.0001.
Data sources: The EPA Integrated Risk Information
System database, 1 January 2004, and the IARC
Monographs Programme on the Evaluation of
Carcinogenic Risks to Humans, Volumes 1–82, 1
January 2004.
Reproduced from Knight et al. (3).

4) the considerable variability of organ systems in
response to carcinogenic insults, within and
between species; and 5) the inherent predisposition of chronic high-dose bioassays toward false
positive results, due to the overwhelming of physiological defences, and the unnatural elevation of
cell division rates during ad libitum feeding studies (4). These factors, reviewed in detail in Knight
et al. (4), render profoundly difficult any attempts
to accurately extrapolate human carcinogenic hazard from animal data.
Furthermore, the IARC assessments for the same
chemicals indicate that the human predictivity of
animal carcinogenicity data is probably even poorer
than that indicated by the EPA figures alone. The
EPA and IARC carcinogenicity classifications were
similar only for chemicals possessing human data.
For the remainder (the great majority), the EPA
was much more likely than the IARC to assign carcinogenicity classifications indicative of greater
human hazard. The IARC is recognised as one of
the most authoritative sources of information on
potential human carcinogens (6, 7), and it is
implausible that IARC assessments would, in general, be inaccurate or based on incomplete data.
Consequently, the significant differences in human
carcinogenicity classifications of identical chemicals
between the IARC and the EPA indicate that: 1) in
the absence of significant human data the EPA is

Alternatives to the Bioassay
Conventional animal carcinogenicity tests take
around three years to design, conduct and interpret
(8). They have so far consumed hundreds of millions of dollars (9), millions of skilled personnel
hours (10), and millions of animal lives (8, 10).
However, several investigations (6, 11–17) have
illustrated the poor human specificity, and hence,
poor predictivity, of animal carcinogenicity data.
Clearly, more-predictive alternatives to the conventional rodent bioassay are required, particularly for
use in large-scale testing programs such as the
REACH system.
Proposed bioassay modifications have included: the
elimination of mice; the use of genetically-altered
mice that exhibit the altered expression of genes
mechanistically relevant to carcinogenesis; neonatal
mice; decreased timeframes; initiation-promotion
models, which employ non-carcinogenic promoters to
speed the effects of carcinogenic initiators, or viceversa; greater incorporation of toxicokinetic and toxicodynamic assessments; computerised quantitative
structure-activity relationship (QSAR) systems,
which predict and quantify carcinogenic effects based
on the presence of electrophilic molecular substructures or other chemical moieties; enhanced in vitro
assays; cDNA microarrays containing hundreds or
thousands of complementary DNA transcripts of
mRNA templates, which can be used to detect genetic
expression changes caused by carcinogens (toxicogenomics); limited human clinical trials; and epidemiological research (18).
Based on our detailed review of these bioassay
alternatives in Knight et al. (18), we propose the
replacement of the conventional carcinogenicity
bioassay with the following protocol, based on a
tiered combination of alternative assays.
1. Before any assay is conducted, all existing information about the test compound should be collated and reviewed in a critical and unbiased
fashion, to determine which tests are scientifically justified.
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2. Initial screens should include computerised
QSAR systems, cell or tissue cultures, and cDNA
microarrays, where possible. QSAR systems
should be used to identify and estimate the toxic
effects of specific chemical groups. Appropriate
in vitro screening assays, such as the Ames
Salmonella, Syrian Hamster Embryo cell transformation, Saccharomyces GreenScreen, and
human basal and target organ cell or tissue culture assays, should be fully employed to seek
evidence of cytotoxicity, mutagenicity and genotoxicity. Carefully chosen and well-conducted
cDNA microarray assays for genotoxicity and
non-genotoxicity should be used for the detection of changes in genetic expression.
3. Following these initial screens, human toxicological studies with barrier models and biological
simulations, and microdosing and non-invasive
biomarkers, should be appropriately selected to
model toxicokinetics and estimate target organ
concentrations.
4. In the case of human pharmaceuticals, and nonpharmaceuticals for which a human carcinogenicity assessment is also considered of high
importance, and for which human carcinogenicity or other toxicity is not already suggested on
the basis of data acquired through the application of all the other methods specified in stages
1–3, above, limited human trials involving fully
informed and consenting volunteers (phase I
and II human clinical trials in the case of pharmaceuticals) might be conducted, albeit with
considerable caution, commencing with microdoses.
The further development, validation and implementation of some of these alternative assays will
no doubt require a redistribution of funding.
However, the proper collation and examination of
the more-targeted data obtained through such a
testing protocol for evidence of carcinogenic risk
factors such as genotoxicity, immunosuppression,
hormonal activity or chronic irritation/inflammation, is likely to yield a weight-of-evidence characterisation of superior human predictivity when
compared to that offered by the conventional
rodent bioassay. Additional advantages include
the likelihood of greater insights into mechanisms
of carcinogenicity, and substantial saving of financial, human and animal resources (18).
The impending demands of the REACH chemicals testing system are unparalleled in EU history.
Consequently, the further development, validation
and implementation of non-animal carcinogenicity
assays must be accorded the highest priority by
both chemical regulators and the chemical industry.
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